Agios Pharmaceuticals (NASDAQ:AGIO) Price Target Raised to $25.00

Agios Pharmaceuticals (NASDAQ:AGIO) had its price target increased by JPMorgan Chase & Co. from $20.00 to $25.00 in a research report report published on Tuesday morning,Benzinga reports. JPMorgan Chase & Co. currently has a neutral rating on the biopharmaceutical company’s stock.

Other analysts have also issued research reports about the stock. Citigroup restated a “buy” rating on shares of Agios Pharmaceuticals in a research note on Friday, December 26th. The Goldman Sachs Group decreased their price objective on shares of Agios Pharmaceuticals from $40.00 to $25.00 and set a “neutral” rating for the company in a report on Thursday, November 20th. Bank of America upped their target price on shares of Agios Pharmaceuticals from $32.00 to $34.00 and gave the company a “buy” rating in a research note on Wednesday, December 24th. Weiss Ratings reiterated a “sell (d)” rating on shares of Agios Pharmaceuticals in a research note on Monday, December 29th. Finally, Wall Street Zen lowered Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, November 22nd. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Agios Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $39.44.

Agios Pharmaceuticals Stock Performance

NASDAQ:AGIO opened at $28.16 on Tuesday. Agios Pharmaceuticals has a one year low of $22.24 and a one year high of $46.00. The business’s 50-day simple moving average is $31.00 and its 200 day simple moving average is $35.76. The stock has a market cap of $1.64 billion, a price-to-earnings ratio of -4.02 and a beta of 0.89.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported ($1.78) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.93) by $0.15. Agios Pharmaceuticals had a negative return on equity of 28.35% and a negative net margin of 895.86%.The firm had revenue of $12.88 million during the quarter, compared to analyst estimates of $10.49 million. During the same quarter last year, the firm earned $16.22 EPS. Agios Pharmaceuticals’s quarterly revenue was up 43.3% on a year-over-year basis. On average, equities research analysts predict that Agios Pharmaceuticals will post -6.85 EPS for the current year.

Insider Buying and Selling

In other news, insider Sarah Gheuens sold 3,302 shares of the stock in a transaction that occurred on Monday, October 27th. The stock was sold at an average price of $43.92, for a total transaction of $145,023.84. Following the sale, the insider directly owned 61,727 shares in the company, valued at approximately $2,711,049.84. This represents a 5.08% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Cecilia Jones sold 2,932 shares of the company’s stock in a transaction on Tuesday, December 30th. The stock was sold at an average price of $27.09, for a total value of $79,427.88. Following the transaction, the chief financial officer owned 37,394 shares of the company’s stock, valued at approximately $1,013,003.46. The trade was a 7.27% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 37,005 shares of company stock valued at $1,064,531 over the last 90 days. 4.30% of the stock is owned by corporate insiders.

Institutional Trading of Agios Pharmaceuticals

Several hedge funds have recently bought and sold shares of the company. Wellington Management Group LLP raised its position in shares of Agios Pharmaceuticals by 485.5% during the 3rd quarter. Wellington Management Group LLP now owns 2,471,416 shares of the biopharmaceutical company’s stock worth $99,203,000 after buying an additional 2,049,287 shares in the last quarter. TCG Crossover Management LLC increased its stake in shares of Agios Pharmaceuticals by 105.2% during the third quarter. TCG Crossover Management LLC now owns 1,430,041 shares of the biopharmaceutical company’s stock valued at $57,402,000 after acquiring an additional 733,038 shares during the period. SCS Capital Management LLC acquired a new position in shares of Agios Pharmaceuticals during the first quarter valued at approximately $17,905,000. Balyasny Asset Management L.P. bought a new stake in Agios Pharmaceuticals during the third quarter worth approximately $19,889,000. Finally, Erste Asset Management GmbH lifted its position in Agios Pharmaceuticals by 18.8% in the third quarter. Erste Asset Management GmbH now owns 2,764,900 shares of the biopharmaceutical company’s stock worth $108,578,000 after purchasing an additional 438,411 shares during the period.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.